#United States #New York #Class Action #Securities Fraud #Altimmune

Class Action Lawsuit Against Altimmune, Inc.

On August 12, 2025, Levi & Korsinsky, LLP issued a notice to investors regarding a class action securities lawsuit filed against Altimmune, Inc. This alert is particularly relevant for investors who faced losses due to alleged securities fraud during the specified period from August 10, 2023, to June 25, 2025. The focus of the lawsuit is to seek compensation for those adversely affected by the actions of the company during this time.

Background of the Case

The crux of the lawsuit is tied to the company's announcement on June 26, 2025, concerning the results from their IMPACT Phase 2b trial of Pemvidutide, aimed at the treatment of MASH (metabolic associated fatty liver disease). Prior to the announcement, Altimmune maintained an optimistic outlook about the trial outcomes, which led many investors to believe in the company’s projected success. However, the actual results revealed that the trial failed to achieve statistical significance in its primary analysis regarding the reduction of fibrosis.

This unexpected outcome was noted to arise from a greater-than-anticipated placebo response, leading to a significant downturn in investor confidence. On June 25, 2025, Altimmune’s shares closed at $7.71 each, only to plummet to $3.61 the following day, marking a staggering decline of 53.2% in just a single trading session.

Implications for Investors

Investors who witnessed a loss during the relevant period are urged to take note of the upcoming deadline for participating in the lawsuit. These individuals have until October 6, 2025, to request the court's appointment as the lead plaintiff. Importantly, it should be noted that participation in potential recovery does not require serving in this role.

The law firm emphasizes that there are no fees or costs involved for class members, and they may be entitled to compensation regardless of their financial situation.

Levi & Korsinsky's Expertise

Levi & Korsinsky, known for their robust history of representing investors in complex securities litigation, has managed to secure hundreds of millions for aggrieved shareholders over the past two decades. The firm has been recognized consistently in the ISS Securities Class Action Services' Top 50 Report, further solidifying its reputation as one of the leading securities litigation firms in the United States.

The legal team, consisting of over 70 members, is committed to serving investors and addressing their concerns regarding this pressing issue. Stakeholders are encouraged to reach out for more information regarding their rights and potential avenues for compensation.

For those interested, Joseph E. Levi, Esq. can be contacted via email at [email protected] or by phone at (212) 363-7500.

Conclusion

The announcement of this class action lawsuit is a critical development for investors in Altimmune, Inc. As the deadline approaches, it is imperative for affected parties to stay informed and take appropriate action to ensure their interests are represented effectively. This case highlights the importance of due diligence and the potential repercussions of corporate mismanagement and inaccurate disclosures.